A246 VMP Results in Fewer Bone Events and Greater ALP Increases Versus MP in the VISTA Study in Front-Line MM

M Delforge; M.J. Kropff; Ivan Špička; M. Petrucci; PG Richardson; Rudolf Schlag; N Khuageva; Meletios A Dimopoulos; Ofer Shpilberg; Olga Samoilova; MV Mateos; K Liu; William Deraedt; Helgi van de Velde; Jesús F. San Miguel

doi:10.1016/s1557-9190(11)70521-2

Related publications

Article2009

A232 Superior Survival with VMP Versus MP After Longer Follow-up and Response to Subsequent Therapy in VISTA

Jesús F. San Miguel, Meletios A Dimopoulos, Rudolf Schlag, Nuriet K. Khuageva, Ofer Shpilberg, Martin Kropff, Maria Teresa Petrucci, Antonio Palumbo, Olga Samoilova, Anna Dmoszyńska, Abdulkadyrov Km, Rik Schots, Baoguo Jiang, MV Mateos, KC Anderson, DL Esseltine, K Liu, Andrew Cakana, Helgi van de Velde, PG Richardson

Article2009

VMP in Renally Impaired Newly Diagnosed MM Patients: Cohort Analysis of the VISTA Study

Meletios A Dimopoulos, PG Richardson, Rudolf Schlag, N Khuageva, Ofer Shpilberg, Efstathios Kastritis, Martin Kropff, MT Petrucci, Michel Delforge, Julia Alexeeva, Henri Schots, Tamás Masszi, MV Mateos, William Deraedt, KeXin Liu, Andrew Cakana, Ann Van de Velde, Jesús F. San Miguel

Article2009

A166 VMP in Renally Impaired Newly Diagnosed MM Patients: Cohort Analysis of the VISTA Study

Meletios A Dimopoulos, PG Richardson, Rudolf Schlag, N Khuageva, Ofer Shpilberg, Efstathios Kastritis, Martin Kropff, Maria das Graças Ribeiro Moreira Petruci, Michel Delforge, Julia Alexeeva, Rik Schots, Tamás Masszi, MV Mateos, V Deraedt, K Liu, Andrew Cakana, Helgi van de Velde, Jesús F. San Miguel

Article2008

Prolonged therapy with bortezomib plus melphalan-prednisone (vmp) results in improved quality and duration of response in the phase iii vista study in previously untreated multiple myeloma (mm)

Antonio Palumbo, Rudolf Schlag, Nuriet K. Khuageva, Ofer Shpilberg, Meletios A Dimopoulos, Martin Kropff, Ivan Špıčka, MT Petrucci, Michel Delforge, MV Mateos, Dixie‐Lee Esseltine, K Liu, William Deraedt, H. Van de Velde, Paul G. Richardson, JF San-Miguel

Article2009

A084 Similar Benefit in Patients Aged q 75 Years Versus < 75 Years with VMP in First-Line MM and Bortezomib in Relapsed MM

Martin Kropff, PG Richardson, Rudolf Schlag, N Khuageva, Meletios A Dimopoulos, Ofer Shpilberg, Rik Schots, MT Petrucci, Rachel Neuwirth, Anthony Boral, Andrew Cakana, K Liu, William Deraedt, H. Van de Velde, Jesús F. San Miguel

A246 VMP Results in Fewer Bone Events and Greater ALP Increases Versus MP in the VISTA Study in Front-Line MM

Discussion(0)

Related publications

A232 Superior Survival with VMP Versus MP After Longer Follow-up and Response to Subsequent Therapy in VISTA

VMP in Renally Impaired Newly Diagnosed MM Patients: Cohort Analysis of the VISTA Study

A166 VMP in Renally Impaired Newly Diagnosed MM Patients: Cohort Analysis of the VISTA Study

Prolonged therapy with bortezomib plus melphalan-prednisone (vmp) results in improved quality and duration of response in the phase iii vista study in previously untreated multiple myeloma (mm)

A084 Similar Benefit in Patients Aged q 75 Years Versus &lt; 75 Years with VMP in First-Line MM and Bortezomib in Relapsed MM

A084 Similar Benefit in Patients Aged q 75 Years Versus < 75 Years with VMP in First-Line MM and Bortezomib in Relapsed MM